General Information of Drug (ID: DM09Z35)

Drug Name
bilobalide Drug Info
Synonyms
Bilobalide; 33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
73581
ChEBI ID
CHEBI:3103
CAS Number
CAS 33570-04-6
TTD Drug ID
DM09Z35

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Glycine receptor (GlyR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [5]
ZD-9379 DM3KYO4 Cerebrovascular ischaemia 8B1Z Phase 1 [6]
UK-240455 DMSCXB7 Nerve injury ND56.4 Phase 1 [7]
MDL-27531 DMC60S8 Epilepsy 8A60-8A68 Phase 1 [8]
Gavestinel DM8IL1U Nerve injury ND56.4 Discontinued in Phase 2 [9]
GV-196771 DMFN21T Migraine 8A80 Discontinued in Phase 2 [10]
GW 468816 DMQ92WF Tobacco dependence 6C4A.2 Discontinued in Phase 2 [11]
M-241247 DMIY51U Cerebrovascular ischaemia 8B1Z Terminated [12]
GINKOLIDE B DMLIM7B Sepsis 1G40-1G41 Terminated [13]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3B receptor (HTR3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [14]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [15]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [16]
QUIPAZINE DMPY6IG Discovery agent N.A. Investigative [15]
MESULERGINE DMKGWAH Discovery agent N.A. Investigative [17]
2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 Discovery agent N.A. Investigative [15]
BRL-24682 DMSB4EW Discovery agent N.A. Investigative [18]
6-(4-Methyl-piperazin-1-yl)-phenanthridine DM1HAWR Discovery agent N.A. Investigative [15]
trichloroethanol DMNALMF Discovery agent N.A. Investigative [19]
1-phenylbiguanide DMA4XGL Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [21]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [22]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [23]
Palonosetron DMBHMOX Nausea MD90 Approved [24]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [23]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [25]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [26]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [14]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [27]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [28]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Blocker (channel blocker) [2]
5-HT 3B receptor (HTR3B) TTR6K75 5HT3B_HUMAN Blocker (channel blocker) [3]
Glycine receptor (GlyR) TTZ8EM9 GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN Antagonist [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2366).
2 Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. 2011 Jul;80(1):183-90.
3 Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427).
5 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
6 Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
7 UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
8 MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
9 Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54.
10 First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6.
11 A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
13 Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
14 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
15 Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
16 The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
17 Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
18 Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
19 Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
20 Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
21 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
22 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
23 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
24 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
25 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
26 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
27 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
28 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.